Business Context and Reporting Period
Electromed, Inc. develops, manufactures and markets SmartVest airway-clearance systems using High Frequency Chest Wall Oscillation therapy. Its customers include home-care patients, hospitals, clinics, distributors and international customers.
The filing is a Form 10-Q for the quarter ended March 31, 2021, representing fiscal 2021 third-quarter results. The request metadata identifies “2020 Q3,” but the filing itself clearly reports March 31, 2021 and comparisons with March 31, 2020.
Financial Performance and Liquidity
| Metric | Three Months Ended March 31, 2021 | Year-over-Year Change | Nine Months Ended March 31, 2021 | Year-over-Year Change |
|---|---|---|---|---|
| Net revenue | $8.787 million | +0.5% | $26.287 million | +2.7% |
| Gross profit | $6.701 million | +1.6% | $20.374 million | +3.9% |
| Gross margin | 76.3% | Up from 75.4% | 77.5% | Up from 76.6% |
| Operating income | $0.243 million | Down from $0.913 million | $2.489 million | Down from $3.829 million |
| Net income | $0.224 million | Down 65.7% | $1.962 million | Down 31.2% |
| Diluted earnings per share | $0.03 | Down from $0.07 | $0.22 | Down from $0.33 |
- Home-care revenue increased 4.2% in the quarter and 6.7% year to date, driven by higher referrals and approvals, increased Medicare revenue and the company’s hybrid sales model.
- Institutional revenue declined 27.3% in the quarter and 40.4% year to date because of reduced hospital purchasing activity during COVID-19.
- SG&A increased 14.4% in the quarter and 8.9% year to date, primarily from additional sales and marketing personnel, systems investments, incentive compensation and professional fees.
- Research and development expense increased 120.2% year to date because of next-generation platform development activities.
- Cash flow from operations was $2.325 million for the nine months ended March 31, 2021, compared with $2.912 million in the prior-year period.
- Cash increased to $12.501 million at March 31, 2021 from $10.479 million at June 30, 2020. Working capital was approximately $28.050 million.
- Investing cash outflows were $0.208 million, including $0.105 million for property and equipment and $0.103 million for patent costs.
- Financing cash outflows were $0.095 million, principally reflecting $0.141 million of taxes paid on net share settlements, partially offset by proceeds from option exercises.
- The company had no borrowings outstanding under its renewed $2.5 million revolving credit facility. The full $2.5 million was available at March 31, 2021, subject to borrowing terms and covenants.
Material Changes Versus the Prior Comparable Period
- Revenue growth was modest overall as home-care gains largely offset COVID-19-related declines in institutional and international sales.
- Gross margin improved because of a greater mix of home-care revenue and favorable Medicare mix.
- Operating income and net income declined substantially as operating expenses grew faster than revenue.
- Accounts receivable increased by $3.296 million during the first nine months, primarily because Medicare home-care revenue has a 13-month payment cycle.
- Inventory declined by $0.839 million, while accounts payable and accrued liabilities increased by $1.219 million.
- International revenue declined 34.7% year to date, and home-care distributor revenue increased 3.8% year to date despite a quarterly decline.
- The effective tax rate was 11.5% for the quarter and 22.0% year to date, aided by discrete tax benefits totaling $37,000 for the quarter and an additional $32,000 benefit related to stock-option exercises year to date.
Guidance, Outlook, Risks and Unusual Items
- Management expects current working capital, operating cash flow and available credit to provide adequate liquidity during fiscal 2021.
- Management expects research and development investment to remain at a similar range through calendar 2021 and plans continued systems-infrastructure investments, including an enterprise resource planning implementation.
- The COVID-19 pandemic continues to affect clinic access, patient referrals, hospital purchasing and institutional orders. Management reported improved home-care referrals and approvals but expects pandemic effects to continue through the remainder of fiscal 2021.
- CMS reimbursement waivers for Medicare respiratory products were extended for an additional 90-day period beginning April 21, 2021; the company indicated the waiver was otherwise effective until July 2021. Expiration or modification could reduce referrals and approval rates.
- The company reported minor supply-chain timing changes and higher product costs but no material adverse supply-chain impact as of the filing date. Future disruptions or cost increases could reduce gross margins.
- The credit facility expires December 18, 2021 unless renewed. Failure to meet covenants or obtain renewal could restrict access to funds, accelerate obligations or result in foreclosure on pledged assets.
- Key additional risks include changes to Medicare, Medicaid or private reimbursement; medical-device regulation; competition; international sales; intellectual-property protection; sales-force expansion; and the ability to develop new distribution channels.
- The company reported no material undisclosed litigation, no off-balance-sheet arrangements and no defaults. The warranty reserve remained $0.740 million.
Important Facts for Investors to Verify
- Confirm the sustainability of home-care referral and Medicare growth after the CMS waiver expires or changes.
- Monitor recovery of institutional and international revenue as healthcare facilities resume normal purchasing and clinical activity.
- Assess whether SG&A, R&D and planned technology investments can be supported by revenue growth without further compressing operating margins.
- Review accounts-receivable aging, Medicare collection trends and the company’s assumptions for variable consideration and contract assets.
- Verify renewal of the $2.5 million revolving credit facility before its December 18, 2021 expiration and ongoing compliance with its covenants.
- Evaluate COVID-19 developments, supply-chain costs, reimbursement-policy changes and regulatory or competitive pressures.